Impact of gender-affirming hormone therapy on kidney function examined
Gender-affirming hormone therapy is associated with increased serum creatinine in transgender men, but not in transgender women, according to a systematic review and meta-analysis published online 16 August in the Clinical Journal of the American Society of Nephrology.
Emily Krupka, RN, from Seven Oaks General Hospital in Winnipeg, Canada, and colleagues conducted a systematic review to characterise the change in serum creatinine, other kidney function biomarkers, and glomerular filtration rate in transgender persons initiating masculinising and feminising gender-affirming hormone therapy (GAHT).